This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Indian generics muscle into global weight-loss gold rush as Novo Nordisk's patent crumbles

By Freny Patel ( December 19, 2025, 01:29 GMT | Comment) -- In the high-stakes world of patents, a "thumping victory" in the Delhi High Court has fundamentally rewritten the playbook for India’s pharmaceutical generics giants. Is the next great weight-loss drug battle being fought for the Indian patient, or for the rest of the world where the market is far more lucrative and valued in billions?...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections